For the quarter ended December 2025, Royalty Pharma (RPRX) reported revenue of $874 million, up 17.8% over the same period last year. EPS came in at $1.46, compared to $1.15 in the year-ago quarter.
The reported revenue represents a surprise of +5.95% over the Zacks Consensus Estimate of $824.94 million. With the consensus EPS estimate being $1.33, the EPS surprise was +10.19%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise: $251 million versus $230.74 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change.
- Portfolio Receipts- Royalty Receipts- Products- Tysabri: $65 million versus $64.05 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
- Portfolio Receipts- Royalty Receipts- Products- Imbruvica: $40 million compared to the $41.09 million average estimate based on two analysts. The reported number represents a change of -13% year over year.
- Portfolio Receipts- Royalty Receipts- Products- Xtandi: $53 million versus the two-analyst average estimate of $49.32 million. The reported number represents a year-over-year change of +15.2%.
- Portfolio Receipts- Royalty Receipts- Products- Promacta: $27 million versus $22.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -38.6% change.
- Portfolio Receipts- Royalty Receipts- Products- Tremfya: $56 million compared to the $57.66 million average estimate based on two analysts. The reported number represents a change of +43.6% year over year.
- Portfolio Receipts- Milestones and other contractual receipts: $18 million versus $11.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +38.5% change.
- Portfolio Receipts- Royalty Receipts- Products- Evrysdi: $64 million versus the two-analyst average estimate of $58.83 million. The reported number represents a year-over-year change of +14.3%.
- Portfolio Receipts- Royalty Receipts- Products- Trodelvy: $12 million versus $11.79 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
- Portfolio Receipts- Royalty Receipts- Products- Total: $856 million versus $813.54 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +17.4% change.
- Portfolio Receipts- Royalty Receipts- Products- Trelegy: $95 million versus the two-analyst average estimate of $93.7 million. The reported number represents a year-over-year change of +28.4%.
- Portfolio Receipts- Royalty Receipts- Products- Spinraza: $14 million versus the two-analyst average estimate of $13.37 million. The reported number represents a year-over-year change of -6.7%.
View all Key Company Metrics for Royalty Pharma here>>>
Shares of Royalty Pharma have returned +9.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Royalty Pharma PLC (RPRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
